Veterinary Medicines

Virbagen canis SHA/L, Lyophilisat und Suspension zur Herstellung einer Injektionssuspension für Hunde

Authorised
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain 601895, Inactivated
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 601903, Inactivated
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine distemper virus, strain Lederle, Live
Download as PDF

Product identification

Medicine name:
Virbagen canis SHA/L, Lyophilisat und Suspension zur Herstellung einer Injektionssuspension für Hunde
Active substance:
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain 601895, Inactivated
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 601903, Inactivated
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine distemper virus, strain Lederle, Live
Target species:
  • Dog (puppy)
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain 601895, Inactivated
    6910.00
    enzyme-linked immunosorbent assay unit
    /
    1.00
    millilitre(s)
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 601903, Inactivated
    7330.00
    enzyme-linked immunosorbent assay unit
    /
    1.00
    millilitre(s)
  • Canine adenovirus 2, strain Manhattan, Live
    1000000.00
    50% tissue culture infectious dose
    /
    1.00
    Dose
  • Canine distemper virus, strain Lederle, Live
    100000.00
    50% tissue culture infectious dose
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and suspension for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AI01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Germany
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Virbac Tierarzneimittel GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Virbac
Responsible authority:
  • Paul-Ehrlich-Institut
Authorisation number:
  • 154a/80
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
German (PDF)
Published on: 26/04/2022
Download